MX373365B - Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). - Google Patents
Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).Info
- Publication number
- MX373365B MX373365B MX2016006815A MX2016006815A MX373365B MX 373365 B MX373365 B MX 373365B MX 2016006815 A MX2016006815 A MX 2016006815A MX 2016006815 A MX2016006815 A MX 2016006815A MX 373365 B MX373365 B MX 373365B
- Authority
- MX
- Mexico
- Prior art keywords
- tam
- inhibitors
- tyro3
- axl
- family kinases
- Prior art date
Links
- 150000003927 aminopyridines Chemical class 0.000 title abstract 2
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108091077303 mer family Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 108091077436 Tam family Proteins 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361909830P | 2013-11-27 | 2013-11-27 | |
| US201361909828P | 2013-11-27 | 2013-11-27 | |
| PCT/US2014/067709 WO2015081257A2 (en) | 2013-11-27 | 2014-11-26 | Aminopyridine derivatives as tam family kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006815A MX2016006815A (es) | 2016-12-02 |
| MX373365B true MX373365B (es) | 2020-05-26 |
Family
ID=52146717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006815A MX373365B (es) | 2013-11-27 | 2014-11-26 | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). |
| MX2020005181A MX2020005181A (es) | 2013-11-27 | 2016-05-25 | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005181A MX2020005181A (es) | 2013-11-27 | 2016-05-25 | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10233176B2 (enExample) |
| EP (1) | EP3074390B1 (enExample) |
| JP (1) | JP6496731B2 (enExample) |
| KR (1) | KR102398473B1 (enExample) |
| CN (2) | CN105764514B (enExample) |
| AU (1) | AU2014354711B2 (enExample) |
| BR (1) | BR112016012146B1 (enExample) |
| CA (1) | CA2930324C (enExample) |
| IL (1) | IL245660B (enExample) |
| MX (2) | MX373365B (enExample) |
| WO (1) | WO2015081257A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| AU2018338314B2 (en) | 2017-09-22 | 2024-12-12 | Kymera Therapeutics, Inc | Protein degraders and uses thereof |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2020010210A1 (en) * | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Mertk degraders and uses thereof |
| EP3817748A4 (en) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | TRICYCLIC CRBN LIGANDS AND USES THEREOF |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| BR112021005054A2 (pt) * | 2018-09-18 | 2021-06-08 | Signalchem Lifesciences Corporation | terapia de combinação para tratamento contra câncer no sangue |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12521438B2 (en) | 2019-06-10 | 2026-01-13 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022551522A1 (en) | 2019-12-23 | 2024-01-29 | Kymera Therapeutics Inc | Smarca degraders and uses thereof |
| PH12022552458A1 (en) | 2020-03-19 | 2024-01-22 | Kymera Therapeutics Inc | Mdm2 degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| CN112707898A (zh) * | 2020-12-21 | 2021-04-27 | 徐新杰 | 一种杂芳基取代的吡嗪衍生物及其应用 |
| MX2023007852A (es) | 2020-12-30 | 2023-07-07 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| EP4284368B1 (en) * | 2021-02-01 | 2024-12-11 | SignalChem Lifesciences Corporation | Use of the axl inhibitor slc-391 as antiviral therapeutic agent |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| WO2025170888A1 (en) | 2024-02-05 | 2025-08-14 | Signalchem Lifesciences Corporation | A combination of the axl inhibitor slc-391 and a pd-1 inhibitor for use in the treatment of blood cancer |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7884119B2 (en) | 2005-09-07 | 2011-02-08 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as Axl inhibitors |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| CA2646701A1 (en) * | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
| EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
| US7879856B2 (en) | 2006-12-22 | 2011-02-01 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles useful as Axl inhibitors |
| PT2078010E (pt) | 2006-12-29 | 2014-05-07 | Rigel Pharmaceuticals Inc | Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl |
| EP2484679B1 (en) | 2006-12-29 | 2016-09-28 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors |
| EP2114954B1 (en) | 2006-12-29 | 2013-02-13 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| CA2710230C (en) | 2006-12-29 | 2016-02-23 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2079736B1 (en) | 2006-12-29 | 2017-10-18 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| AU2008240188A1 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
| WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2703653A1 (en) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Pyridine and pyrazine derivatives -083 |
| JP5635909B2 (ja) | 2007-10-26 | 2014-12-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌ阻害剤として有用な多環アリール置換トリアゾール及び多環ヘテロアリール置換トリアゾール |
| WO2009099982A1 (en) * | 2008-02-04 | 2009-08-13 | Osi Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| CA2716949A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| JP5746015B2 (ja) | 2008-04-16 | 2015-07-08 | マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー | Ａｘｌキナーゼ阻害剤としてのキノリン誘導体 |
| US8349838B2 (en) | 2008-07-09 | 2013-01-08 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
| SI2328888T1 (sl) * | 2008-07-09 | 2013-03-29 | Rigel Pharmaceuticals, Inc. | Premoščeni biciklični heteroaril substituirani triazoli, uporabni kot inhibitorji Axl |
| BRPI1007046B1 (pt) | 2009-01-16 | 2019-07-16 | Rigel Pharmaceuticals, Inc. | Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático. |
| WO2010090764A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
| EP2311809A1 (en) | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| JP5675850B2 (ja) * | 2010-02-05 | 2015-02-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ヘタリール−［１，８］ナフチリジン誘導体 |
| WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| AU2011253021A1 (en) * | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of ATR kinase |
| EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| WO2012087938A1 (en) * | 2010-12-20 | 2012-06-28 | Glaxosmithkline Llc | Quinazolinone derivatives as antiviral agents |
| ES2759615T3 (es) | 2011-04-01 | 2020-05-11 | Univ Utah Res Found | Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL |
| DK2780338T3 (en) | 2011-11-14 | 2016-12-19 | Ignyta Inc | Uracil AS AXL- AND C-MET kinase inhibitors |
| CA2863515C (en) | 2012-01-31 | 2018-02-27 | Daiichi Sankyo Company, Limited | Pyridone derivatives |
| WO2013162061A1 (ja) | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | 二環性ピリミジン化合物 |
| CN104903311B (zh) * | 2013-01-02 | 2016-11-09 | H.隆德贝克有限公司 | 作为lrrk2抑制剂的氨基吡啶衍生的化合物 |
-
2014
- 2014-11-26 CN CN201480065032.8A patent/CN105764514B/zh active Active
- 2014-11-26 MX MX2016006815A patent/MX373365B/es active IP Right Grant
- 2014-11-26 JP JP2016534735A patent/JP6496731B2/ja active Active
- 2014-11-26 US US15/039,609 patent/US10233176B2/en active Active
- 2014-11-26 CA CA2930324A patent/CA2930324C/en active Active
- 2014-11-26 EP EP14819178.6A patent/EP3074390B1/en active Active
- 2014-11-26 WO PCT/US2014/067709 patent/WO2015081257A2/en not_active Ceased
- 2014-11-26 KR KR1020167016444A patent/KR102398473B1/ko active Active
- 2014-11-26 AU AU2014354711A patent/AU2014354711B2/en active Active
- 2014-11-26 CN CN201910548630.5A patent/CN110156770B/zh active Active
- 2014-11-26 BR BR112016012146-5A patent/BR112016012146B1/pt active IP Right Grant
-
2016
- 2016-05-16 IL IL245660A patent/IL245660B/en active IP Right Grant
- 2016-05-25 MX MX2020005181A patent/MX2020005181A/es unknown
-
2019
- 2019-01-22 US US16/254,208 patent/US10723725B2/en active Active
-
2020
- 2020-06-11 US US16/899,494 patent/US11034686B2/en active Active
- 2020-06-11 US US16/899,489 patent/US11034685B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL245660A0 (en) | 2016-06-30 |
| AU2014354711B2 (en) | 2018-10-25 |
| MX2020005181A (es) | 2020-08-17 |
| US20170022189A1 (en) | 2017-01-26 |
| CN110156770B (zh) | 2022-10-04 |
| MX2016006815A (es) | 2016-12-02 |
| US20200299287A1 (en) | 2020-09-24 |
| US20200299288A1 (en) | 2020-09-24 |
| JP6496731B2 (ja) | 2019-04-03 |
| EP3074390A2 (en) | 2016-10-05 |
| KR102398473B1 (ko) | 2022-05-16 |
| BR112016012146A8 (pt) | 2018-01-30 |
| WO2015081257A3 (en) | 2015-07-02 |
| EP3074390B1 (en) | 2020-07-08 |
| WO2015081257A2 (en) | 2015-06-04 |
| BR112016012146B1 (pt) | 2022-11-01 |
| BR112016012146A2 (pt) | 2017-08-08 |
| US11034685B2 (en) | 2021-06-15 |
| US11034686B2 (en) | 2021-06-15 |
| CN105764514A (zh) | 2016-07-13 |
| US20190152965A1 (en) | 2019-05-23 |
| US10723725B2 (en) | 2020-07-28 |
| CA2930324A1 (en) | 2015-06-04 |
| JP2017501981A (ja) | 2017-01-19 |
| CN105764514B (zh) | 2019-07-12 |
| CN110156770A (zh) | 2019-08-23 |
| IL245660B (en) | 2020-01-30 |
| US10233176B2 (en) | 2019-03-19 |
| KR20160091358A (ko) | 2016-08-02 |
| AU2014354711A1 (en) | 2016-06-02 |
| CA2930324C (en) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX373365B (es) | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| PH12016500739B1 (en) | Inhibitors of the fibrolast growth factor receptor | |
| MX374338B (es) | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de cinasas relacionadas con janus. | |
| ECSP15043696A (es) | Compuestos de heteroarilo y sus usos | |
| MX374558B (es) | Compuestos de heteroarilo y sus usos. | |
| NI201500119A (es) | Compuestos de heteroarilo y sus usos | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| CR20150263A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
| UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
| MX373309B (es) | Composiciones antibióticas de ceftolozano. | |
| UY35499A (es) | Indazoles sustituidos con diaminoheteroarilo | |
| BR112017028549A2 (pt) | derivados de pirimidina como inibidores de btk e usos dos mesmos | |
| MX2017004655A (es) | Compuestos de hidroxil purinas y aplicaciones de estos. | |
| MX2020002366A (es) | Imidazoquinolinas sustituidas como agonistas de tlr7. | |
| BR112017018183A2 (pt) | derivados de pirimidina como inibidores de quinase e suas aplicações terapêuticas. | |
| TR201819130T4 (tr) | Sulu Formülasyonlar, Bunların Üretimi Ve Kullanımı | |
| MX2016001694A (es) | Formulacion de vacuna de sacarido. | |
| MY180947A (en) | Ceftolozane antibiotic compositions | |
| MY182434A (en) | Certain chemical entities, compositions, and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |